IRVINE, Calif., February 26, 2026
Johnson & Johnson announced the U.S. launch of CEREGLIDE™ 42, CEREGLIDE™ 57 aspiration catheters, and INNERGLIDE™ 7 delivery aid, completing its CEREGLIDE™ stroke portfolio and reinforcing its aspiration-first approach to ischemic stroke treatment. The newly introduced devices are engineered to enhance distal clot access, aspiration performance, system compatibility, and procedural workflow efficiency, supporting physicians in complex neurovascular interventions.
Multi-Axial Aspiration System for Distal Clot Removal
The CEREGLIDE™ 42 and 57 aspiration catheters are designed with a proprietary variable-stiffness construction, enabling flexible distal navigation and supportive proximal control during thrombectomy procedures. Distal occlusions, particularly in smaller or tortuous vessels such as the M2 segment, present ongoing technical challenges in stroke intervention. The new catheters aim to address these issues by balancing trackability with structural support, providing physicians with greater confidence when navigating challenging anatomy.
Key features include a hydrophilic coating for reduced friction, a radiopaque tip marker for fluoroscopic visibility, and compatibility with TruCourse™ Technology to facilitate smoother device advancement. The system is intended to integrate seamlessly into existing neurointerventional workflows, minimizing device compatibility concerns while offering consistent performance across multiple catheter sizes. By expanding its catheter family to include 42, 57, and 71 options, Johnson & Johnson enhances flexibility in selecting aspiration tools tailored to clot location and vessel anatomy.
INNERGLIDE™ 7 Enhances Large-Bore Delivery
Advertisement
Complementing the new aspiration catheters, the INNERGLIDE™ 7 delivery aid is designed to support the advancement of large-bore systems, including the CEREGLIDE™ 71, to distal clot locations. The device features a hydrophilic-coated shaft, a soft distal tip, and compatibility with 0.024-inch guidewires, enabling smoother navigation and improved support during complex procedures. Large-bore catheter delivery to distal segments has historically required high levels of technical precision, and INNERGLIDE™ 7 is intended to enhance consistency and reduce resistance during advancement.
Stroke remains one of the leading causes of death and long-term disability worldwide. Mechanical thrombectomy has become a standard of care for eligible ischemic stroke patients, with aspiration-first strategies increasingly adopted in clinical practice. By introducing a multi-axial aspiration system designed for distal access, Johnson & Johnson seeks to elevate procedural efficiency and potentially improve patient outcomes in acute stroke management.
Strengthening Neurovascular Innovation Portfolio
The launch of the complete CEREGLIDE™ portfolio reflects Johnson & Johnson’s broader commitment to advancing its MedTech cardiovascular and neurovascular solutions platform. The company continues to invest in technologies aimed at addressing unmet needs in stroke, heart failure, coronary artery disease, and cardiac rhythm disorders. Through device innovation focused on mapping, navigation, miniaturization, and procedural precision, Johnson & Johnson aims to support clinicians with tools that simplify decision-making and enhance treatment consistency.
While forward-looking statements remain subject to market, regulatory, and competitive risks, the expanded CEREGLIDE™ family positions Johnson & Johnson as a significant contributor to the evolving landscape of neurovascular intervention. By prioritizing distal access capability, aspiration performance, and workflow compatibility, the company is reinforcing its strategic focus on advanced stroke care technologies.
Source: Johnson & Johnson press release
